Latest Endostatin Stories
Mechanisms of VEGF inhibitor-induced hypertension need to be better understood and guidelines developed to improve management.
Researchers at the University of Pittsburgh School of Medicine have identified an agent that in lab tests protected the skin and lungs from fibrosis, a process that can ultimately end in organ failure and even death because the damaged tissue becomes scarred and can no longer function properly.
MANHATTAN BEACH, Calif., May 6, 2011 /PRNewswire/ -- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug AfinitorÂ® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.
NANJING, China, March 22 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.
SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc.
Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
Research in mice and human stem cells suggests new therapeutic targets.
Neotropix, a clinical-stage development company focused on neuroendocrine cancer treatments, has started enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010, a tumor-selective naturally-occurring oncolytic virus.
Neotropix(R), Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today that it has begun enrolling neuroendocrine cancer patients into an expanded clinical trial of its lead candidate, NTX-010 (SVV-001), a tumor-selective naturally-occurring oncolytic virus.
- A person in a secondary role, specifically the second most important character (after the protagonist).